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ABSTRACT 
Chemotherapy induced nausea and vomiting is the among most feared and debilitating adverse events experienced by the cancer 
patients. Left unaddressed, CINV symptoms not only decrease quality of life, but may also affect patients’ willingness to continue 
chemotherapy treatment. However, adherence to guideline recommendations continues to be suboptimal therapy, and many patients 
still suffer unnecessarily from CINV. In addition, breakthrough/refractory CINV continues to present particular challenges. The 
development of effective CINV treatments with diverse mechanisms of action has expanded the options available for preventing 
symptoms. The US Food and Drug Administration have recently approved several new therapies for the management of CINV. 
NEPA is a fixed-dose combination of Netupitant (300 mg) plus Palonosetron (0.5 mg). In combination with Dexamethasone, NEPA 
has demonstrated superior efficacy to Palonosetron alone in patients receiving highly or moderately emetogenic chemotherapy. 
Rolapitant is a nextgeneration neurokinin-1receptor antagonist. Both palonosetron and rolapitant have proven particularly effective 
in controlling delayed CINV. Regimens that combine a serotonin 5-hydroxytryptamine–3 receptor antagonist, an NK1 receptor 
antagonist, and a corticosteroid now represent the standard of care for managing both acute and delayed CINV in patients receiving 
highly emetogenic chemotherapy. 
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1.0 INTRODUCTION 
Nausea and vomiting are 2 serious and related side 
effects of cancer chemotherapy. These adverse effects 
can cause significant negative impacts on patients’ 
quality of life and on their ability to comply with 
therapy. Also, nausea and vomiting can result in 
anorexia, decreased performance status, metabolic 
imbalance, wound dehiscence, oesophageal tears, and 
nutritional deficiency despite advances in the prevention 
and management of chemotherapy-induced nausea and 
vomiting (CINV), these side effects remain among the 
most distressing for patients. The use of emerging 
antiemetic medications has reduced the incidence of 
vomiting substantially, but evaluations show that 
approximately 30% to 60% of patients still experience 
either acute or delayed nausea after chemotherapy. 
Serial evaluations throughout the 1980s and into the 
2000s show that, although vomiting has fallen further 
down on the list of side effects that patients perceive as 
being their most severe, nausea remains either the first 
or second most severe side effect of chemotherapy. Risk 
factors for CINV can be divided into patient specific and 
treatment-specific risk factors. Female sex and history 
of motion or morning sickness are clear risk factors for 
nausea and vomiting. Younger age has also been 
correlated with increased risk, although this may be 
explained by the more aggressive chemotherapy 
regimens that tend to be administered to younger 
patients who have more aggressive diseases. Finally, 
alcohol intake tends to be inversely correlated with the 
risk of developing CINV. Many factors contribute to the 
treatment- specific risk, including the emetogenicity of 
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the agents being used the dose and schedule of each 
agent, and in the case of radiation-induced or 
postoperative nausea, the site of radiation or surgery. 
Emetogenicity” refers to an agent’s tendency to cause 
nausea and/or vomiting. Initially described in 1997, the 
Emetogenicity scale, also known as the Hesketh scale, 
divided chemotherapy agents and doses into 5 levels, 
based on their likelihood to cause CINV
1
. Since then, 
the American Society of Clinical Oncology (ASCO) and 
the National Comprehensive Cancer Network (NCCN) 
have modified this scale to be divided into the following 
4 categories.  
 Highly emetogenic: medications or doses that cause 
CINV in >90% of patients. 
 Moderately emetogenic: medications that induce 
CINV in 30% to 90% of patients. 
 Low emetogenic: medications those are associated 
with CINV rates of 10% to 30%. 
 Minimally emetogenic: medications that cause 
CINV in <10% of patients. 
“CINV” is a broad term used to describe the many types 
of nausea and vomiting that can occur in patients with 
cancer. The major subtypes of nausea and vomiting 
associated with chemotherapy are  
 Acute: onset of nausea and vomiting within minutes 
to hours after administration of chemotherapy and 
resolving within 24 hours 
 Delayed: occurs 24 hours or later after 
administration of chemotherapy  
 Anticipatory: occurs before chemotherapy 
administration thought to be an indicator of 
previous poor control of nausea and vomiting  
 Breakthrough/refractory: nausea and vomiting that 
occur despite appropriate prophylaxis; requires the 
use of rescue medications. Because there are so 
many independent and variable risk factors that can 
influence the risk for CINV in any particular 
patient, it becomes paramount for providers to 
individualize the approach to the prevention and 
treatment of CINV in every patient case. 
2.0 Pathophysiology of Nausea and Vomiting 
The vomiting response is controlled centrally by the 
emetic centre present in the CNS, which lies in the 
reticular formation of the brain stem. The emetic centre 
is receives impulses input from the following sources. 
1. The periphery,  
2. The cortex,  
3. Chemoreceptor trigger zone.  
Peripheral pathways are mediated mainly by Serotonin 
(5-HT3) and Neurokinin, the cortical pathway, which is 
responsible for anticipatory emesis, is mediated by the 
dopamine and histamine
2
.The chemoreceptor trigger 
zone, which is a collection of neurons at the base of the 
brain and is exposed to the body’s general circulation, 
mediates signals through all of the above chemokines. 
Once the emetic centre has been triggered, signals are 
then sent to the salutatory, vasomotor, respiratory, and 
cranial centres to activate the organs involved with the 
vomiting reflex, namely the abdominal muscles, 
diaphragm, stomach, and oesophagus
 3
. 
3.0 Pharmacotherapy 
3.1 Available Agents for management 
Before the 1980s, CINV was primarily managed with 
dopamine receptor antagonists. Today, we have a 
multitude of options available, targeting the various 
pathways of the process, to use in the prevention and 
management of CINV
4
. 
5-HT3 receptor antagonists 
Ondansetron was the first US Food and Drug 
Administration (FDA)-approved 5- HT3 antagonist in 
1991. Early trials showed that ondansetron was an 
effective antiemetic for patients receiving cisplatin-
based regimens, and they subsequently showed it to be 
superior to metoclopramide in patients receiving 
cisplatin and noncisplatin regimens
 5
. Currently, four 5-
HT3 receptor antagonists are available in the United 
States—ondansetron, granisetron, dolasetron, and 
palonosetron. Palonosetron, the new est agent, was 
approved in 2003. These agents are believed to prevent 
CINV by antagonizing 5-HT3 receptors either 
peripherally on vagal nerve terminals and/or centrally in 
the chemoreceptor trigger zone
6
, since their 
introduction, 5-HT3 receptor antagonists have become 
part of the cornerstone for CINV prevention, thanks to 
their effectiveness and tolerable side-effect profile. The 
most common adverse effects reported (in their 
respective package insert) with these agents are 
headache and constipation. Transient elevations of liver 
function enzymes and QTC prolongation have also been 
noted.  
NK1 receptor antagonists 
 NK1 receptor antagonists inhibit substance P in 
peripheral and central emetic pathways. Aprepitant was 
the first drug in this class to be approved by the FDA in 
2003
6
. Aprepitant was approved at doses of 125 mg 
orally on day 1 and 80 mg orally on days 2 and 3 for the 
prevention of nausea and vomiting in patients receiving 
highly emetogenic. 
Corticosteroids 
Corticosteroids were first shown to be efficacious for 
CINV in the 1980s, and they are now considered a 
mainstay of antiemetic regimens for the prevention of 
acute and delayed emesis
7
.Although not approved by the 
FDA for CINV, corticosteroids have been found to be 
beneficial when used alone for the prevention of nausea 
and vomiting  in patients receiving low emetogenic 
chemotherapy and to improve efficacy when combined 
with 5-HT3 receptor antagonists in patients receiving 
moderately or highly emetogenic chemotherapies.36-39 
Dexamethasone is the recommended corticosteroid 
according to current guidelines, although no studies 
have been performed comparing available 
corticosteroids
8,9
. 
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Current Practice Guidelines 
Practice guidelines from the NCCN and ASCO are 
available to help providers determine optimal 
prophylaxis and the treatment of CINV
 10, 11
. The NCCN 
Antiemetic Guideline TM, a consensus-based guideline 
that incorporates evidence and expert opinion to make 
recommendations, is revised annually
 12.
ASCO 
guidelines are purely evidence-based guidelines and are 
updated periodically; the last update was in 2011.10. For 
CINV, both guidelines outline primary prophylaxis 
based on the emetogenicity of the patient’s 
chemotherapy: high, moderate, low, and minimal. For 
patients receiving highly emetogenic chemotherapy, 
both guidelines recommend a 3-drug combination that 
includes a 5-HT3 receptor antagonist, an NK1 receptor 
antagonist, and dexamethasone to prevent CINV. The 
NCCN specifies that the preferred 5-HT3 receptor 
antagonist for highly emetogenic chemotherapy is 
palonosetron,
11
 whereas ASCO does not list a preferred 
5-HT3 receptor antagonist. For patients receiving 
moderately emetogenic chemotherapy, the NCCN and 
ASCO recommend a 2-drug combination of a 5-HT3 
receptor antagonist, preferably palonosetron, with 
dexamethasone. Dexamethasone is recommended by 
both organizations for the prevention of CINV in 
patients with low or minimal emetogenic potential. The 
NCCN also lists metoclopramide or prochlorperazine as 
possible alternatives. For patients receiving minimal-
risk chemotherapy, no medications are recommended 
primarily as prophylaxis. 
CONCLUSIONS 
We are concluding that the treatment for Antiemetic 
regimens for particular patients should be evaluated and 
then revaluated at every treatment cycle. At every step 
of a patient’s care, clinicians must incorporate clinical 
decision-making with value-based considerations to 
determine each patient’s individual, most optimal 
approach to treatment but current scenario most of the 
oncologists may prefer Inj. Ondansetron is the primary 
option for the CINV Metaclopromide is used in the 
second line option for CINV. 
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